EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and CM Life Sciences III Inc. (Nasdaq: CMLTU), a life science-focused special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced that the U.S. Securities and Exchange Commission (“SEC”) has declared CM Life Sciences III’s registration statement on Form S-4 relating to the previously announced business combination agreement between EQRx and CM Life Sciences III effective.
